Compound · clinical trials

Nivolumab clinical trials

Also listed in trial records as ABP 206, BCD-263, BMS 936558, BMS936558, CMAB819, MDX 1106, MDX1106, NIVO, ONO 4538, ONO4538, BMS-936558-01

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 276 trials in our USA, Canada, France, Spain, Australia, Italy, Israel, Netherlands, Germany, Mexico, UK, Japan, South Korea, China, Belgium, Poland, Brazil, Taiwan, Denmark, Austria, Czechia, Norway, Turkey, Sweden, Switzerland, Egypt, Singapore, Portugal, Ireland and India registers that name Nivolumab as an intervention. Synced 8 Nov 2026

276Current trials

125Recruiting now

143Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 8 Nov 2026 · Editorial standards

At a glance

Nivolumab is named as an intervention in 276 current clinical trials in our USA, Canada, France, Spain, Australia, Italy, Israel, Netherlands, Germany, Mexico, UK, Japan, South Korea, China, Belgium, Poland, Brazil, Taiwan, Denmark, Austria, Czechia, Norway, Turkey, Sweden, Switzerland, Egypt, Singapore, Portugal, Ireland and India registers. 125 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is National Cancer Institute (NCI) (35). The most-studied condition is Melanoma. The EU clinical trials register (CTIS) separately lists 13 authorised or ongoing trials, 1 with a site in Ireland.

Nivolumab also has an approved-drug profile on this site (FDA label data): Opdivo (Nivolumab) →

Where Nivolumab is approved

All regulators →

Of the three regulators tracked here, the first to approve Nivolumab was the US, on 22 Dec 2014. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)

22 Dec 2014

Opdivo

BLA125554 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

19 Jun 2015

Opdivo

EMA product page

First centralised authorisation

CACanada (Health Canada)

25 Sep 2015

Opdivo

Notice of Compliance 17324

First new-drug NOC

1 EU orphan designation, most recently for treatment of pulmonary neuroendocrine carcinoma (25 Mar 2026, positive)

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Nivolumab

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$183.8m

27,692 prescriptions in 2025 · Opdivo

-2% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Nivolumab works

All drug targets →

Programmed cell death protein 1 inhibitor Inhibitor
Target: PDCD1 programmed cell death 1
✓ In ChEMBL and the Guide to Pharmacology

Other medicines acting on PDCD1

Pembrolizumab Tislelizumab Sintilimab Toripalimab Camrelizumab Cadonilimab Serplulimab Cemiplimab Dostarlimab Pucotenlimab Zimberelimab Penpulimab +8 more

Diseases it has been tested for in clinical trials, by furthest phase

Anal carcinomaPhase 3
Breast cancerPhase 3
CancerPhase 3
Clear cell renal carcinomaPhase 3
Colon carcinomaPhase 3
Colorectal cancerPhase 3
Cutaneous melanomaPhase 3
Esophageal adenocarcinomaPhase 3
Esophageal cancerPhase 3
Esophageal squamous cell carcinomaPhase 3

266 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2108738, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7335, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Nivolumab

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 30 technology appraisals of Nivolumab. 28 are current, and 20 of these recommend it for at least some patients. 2 older appraisals were replaced or withdrawn.

Appraisal	NICE recommendation	Published	Status
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) NICE TA1141	Terminated (no company submission)	17 Mar 2026	Current
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer NICE TA1127	Optimised	4 Feb 2026	Current
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency NICE TA1065	Recommended	28 May 2025	Current
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) NICE TA980	Terminated (no company submission)	5 Jun 2024	Current
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over NICE TA950	Optimised	7 Feb 2024	Current
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer NICE TA876	Recommended	22 Mar 2023	Current
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma NICE TA865	Optimised	8 Feb 2023	Current
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma NICE TA857	Recommended	11 Jan 2023	Current

See all 28 appraisals →

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Nivolumab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 3 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
EU
European Union: Opdivo
EMA product information: package leaflet and summary of product characteristics in every EU language.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Nivolumab

ATC code: L01XC17
ChEMBL: CHEMBL2108738
DrugBank: DB09035
CAS number: 946414-94-4
FDA UNII: 31YO63LBSN
Wikidata: Q7041828
Wikipedia: Nivolumab

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting12545%
Not yet open124%
Active, closed13649%
By invitation31%

Trials by phase

Phase 212746%
Phase 35520%
Phase 1/23513%
Phase 12810%
Observational135%
Phase 2/3104%
Phase 441%
Not applicable41%

Clinical trials of Nivolumab

276 trials

Study	Phase	Status	Lead sponsor	Registers
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials NCT05203172 · Solid Tumors	Phase 4	Recruiting	Pfizer	UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Portugal, Turkey, Canada, Brazil, South Korea, Australia, Israel
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie NCT06031233 · ClinicalTrials.gov ↗ · Oncology, Infusion Reaction	Phase 4	Recruiting	Isala	Netherlands
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma NCT06934057 · ClinicalTrials.gov ↗ · Kidney Cancer, Renal Cell Cancer	Phase 4	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets NCT05317858 · Brain Tumor, Non Small Cell Lung Cancer	Phase 3	Recruiting	InSightec	USA, Canada, South Korea
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab NCT05675410 · ClinicalTrials.gov ↗ · Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma NCT05677490 · ClinicalTrials.gov ↗ · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) NCT06112314 · Advanced Melanoma	Phase 3	Recruiting	Immunocore Ltd	UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Australia
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) NCT06246916 · Melanoma	Phase 3	Recruiting	Regeneron Pharmaceuticals	USA, Canada
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] NCT06264180 · Advanced Melanoma	Phase 3	Recruiting	Replimune, Inc	UK, USA, Germany, France, Spain, Poland
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas NCT06346197 · ClinicalTrials.gov ↗ · Gastric Cancer, MSI-H, Metastatic Cancer	Phase 3	Recruiting	Centre Leon Berard	France
CARE1 Pragmatic Clinical Trial NCT06364631 · Metastatic Kidney Cancer, Metastatic Kidney Carcinoma	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France, Netherlands, Austria, Czechia
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma NCT06488482 · ClinicalTrials.gov ↗ · High-risk Melanoma	Phase 3	Recruiting	Uppsala University	Sweden, Norway
The Sagittarius Trial NCT06490536 · ClinicalTrials.gov ↗ · Colon Cancer Stage II, Colon Cancer Stage III	Phase 3	Recruiting	IFOM ETS - The AIRC Institute of Molecular Oncology	Germany, Spain, Italy
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases NCT06519266 · ClinicalTrials.gov ↗ · Uveal Melanoma, Liver Metastases	Phase 3	Recruiting	Vastra Gotaland Region	Sweden
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% NCT06561386 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). NCT06646276 · Extensive-Stage Small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma NCT06743126 · Melanoma, Cutaneous Malignant, Mucosal Melanoma	Phase 3	Recruiting	Immatics US, Inc	UK, USA, Germany, France, Netherlands, Canada, Israel
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma NCT06794775 · ClinicalTrials.gov ↗ · Malignant Melanoma Stage III	Phase 3	Recruiting	Hildur Helgadottir	Sweden
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated NCT06908993 · ClinicalTrials.gov ↗ · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation	Phase 3	Recruiting	Intergroupe Francophone de Cancerologie Thoracique	France
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial NCT07166406 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada, Mexico
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations NCT07195695 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Boehringer Ingelheim	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164 · Von Hippel-Lindau Disease, Malignant Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, France, Spain, Netherlands, Belgium, Denmark, Poland, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) NCT07541170 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Hoffmann-La Roche	USA, China, Spain, Italy, Poland, Portugal, Canada, Brazil, Japan, South Korea
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma NCT07700979 · Gastric / Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Akeso	USA, China, Germany, Poland
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC NCT07720284 · High-risk Muscle Invasive Urothelial Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma NCT05595447 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult	Phase 2/3	Recruiting	Hospital Regional de Alta Especialidad del Bajio	Mexico
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study NCT05987241 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial NCT06203600 · ClinicalTrials.gov ↗ · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Mexico
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma NCT06581406 · Metastatic Uveal Melanoma	Phase 2/3	Recruiting	Replimune, Inc	UK, USA, Australia
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) NCT07221149 · Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer NCT07392892 · Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer	Phase 2/3	Recruiting	Pfizer	USA, China, France, Spain, Italy, Canada, Japan, Taiwan, Israel
The Drug Rediscovery Protocol (DRUP Trial) NCT02925234 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasm	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer NCT03026140 · ClinicalTrials.gov ↗ · Colon Carcinoma	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) NCT03297606 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) NCT03340129 · ClinicalTrials.gov ↗ · Melanoma Stage Iv	Phase 2	Recruiting	Melanoma Institute Australia	Norway, Australia
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma NCT03406247 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France
Melanoma Metastasized to the Brain and Steroids NCT03563729 · ClinicalTrials.gov ↗ · Malignant Melanoma	Phase 2	Recruiting	Inge Marie Svane	Denmark
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO NCT03815890 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382 · ClinicalTrials.gov ↗ · Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma	Phase 2	Recruiting	National Cancer Institute (NCI)	Israel
Pan Tumor Rollover Study NCT03899155 · Cancer	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients NCT04159818 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin NCT04204837 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of the Skin	Phase 2	Recruiting	Salzburger Landeskliniken	Austria
The IMmunotherapy Pleural 5-ALA PDT NCT04400539 · ClinicalTrials.gov ↗ · Mesotheliomas Pleural, Malignant Pleural Mesothelioma	Phase 2	Recruiting	University Hospital, Lille	France
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT04546399 · ClinicalTrials.gov ↗ · Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Australia, Israel
ONO-4538 Phase II Rollover Study (ONO-4538-98) NCT04566380 · ClinicalTrials.gov ↗ · Pan-tumor	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	Japan, South Korea, Taiwan
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment NCT04875611 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancer	Phase 2	Recruiting	Maria Sklodowska-Curie National Research Institute of Oncology	Poland
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC NCT04912765 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer	Phase 2	Recruiting	National Cancer Centre, Singapore	Singapore
Using ctDNA to Determine Therapies for Lung Cancer NCT04966663 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA	Phase 2	Recruiting	University Health Network, Toronto	Canada
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma NCT05112601 · ClinicalTrials.gov ↗ · Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study NCT05136196 · ClinicalTrials.gov ↗ · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma NCT05257590 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Advanced Cancer	Phase 2	Recruiting	TaiRx, Inc	Taiwan
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC NCT05310643 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial NCT05327686 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8	Phase 2	Recruiting	NRG Oncology	Ireland, Canada, Mexico, Australia, Israel
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer NCT05492123 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms	Phase 2	Recruiting	Hospital Israelita Albert Einstein	Brazil
Immunotherapy in Patients With Early dMMR Rectal Cancer NCT05732389 · ClinicalTrials.gov ↗ · Cancer of Rectum	Phase 2	Recruiting	Odense University Hospital	Denmark
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) NCT05795244 · ClinicalTrials.gov ↗ · Endometrial Neoplasms, Endometrial Cancer	Phase 2	Recruiting	Yonsei University	South Korea
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients NCT05817903 · ClinicalTrials.gov ↗ · Metastatic Renal Cell Carcinoma	Phase 2	Recruiting	Consorzio Oncotech	Italy
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) NCT05845450 · ClinicalTrials.gov ↗ · Colorectal Cancer, Resectable Colorectal Carcinoma	Phase 2	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases NCT05909618 · ClinicalTrials.gov ↗ · Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated Glioblastoma	Phase 2	Recruiting	Sheba Medical Center	Israel
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study NCT05934331 · ClinicalTrials.gov ↗ · Malignant Neoplasms of Digestive Organs	Phase 2	Recruiting	LaNova Medicines Zhejiang Co., Ltd	China
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma NCT06019130 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms	Phase 2	Recruiting	German Society for Pediatric Oncology and Hematology GPOH gGmbH	Germany
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270 · ClinicalTrials.gov ↗ · Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Singapore, Australia
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma NCT06053658 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma	Phase 2	Recruiting	M.D. Anderson Cancer Center	Israel
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) NCT06064097 · ClinicalTrials.gov ↗ · Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Australia, Israel
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer NCT06245356 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency	Phase 2	Recruiting	UNICANCER	France
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer NCT06253611 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma NCT06319196 · ClinicalTrials.gov ↗ · Cutaneous Melanoma, Melanoma Stage IV, Mucosal Melanoma	Phase 2	Recruiting	University Health Network, Toronto	Canada
CD8 PET Imaging in Metastatic Solid Tumours NCT06534190 · ClinicalTrials.gov ↗ · Locally Advanced Solid Tumor	Phase 2	Recruiting	University Medical Center Groningen	Spain, Netherlands
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC NCT06554613 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Second Affiliated Hospital of Nanchang University	China
Study to ONO-4538 in Patients With Rhabdoid Tumor NCT06622941 · ClinicalTrials.gov ↗ · Rhabdoid Tumor	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	Japan
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy NCT06667154 · ClinicalTrials.gov ↗ · Lung Cancer, Nonsmall Cell, Non-Small Cell Lung Cancer NSCLC	Phase 2	Recruiting	Aline Fusco Fares, MD	Brazil
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab NCT06816927 · ClinicalTrials.gov ↗ · Newly Diagnosed Glioblastoma	Phase 2	Recruiting	Duke University	Australia
Towards Cure Via Only Ultra-short ICB in CSCC NCT06823479 · ClinicalTrials.gov ↗ · Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer, Cutaneous Squamous Cell Carcinoma of the Head and Neck	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
ONO-4538 Study in Patients With Richter's Transformation NCT06936943 · ClinicalTrials.gov ↗ · Richter's Transformation	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	Japan
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer NCT06948448 · Colorectal Cancer	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	USA, France, Spain, Italy, Canada, Japan
Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer NCT07084610 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Hospital das Clínicas de Ribeirão Preto	Brazil
Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab NCT07100704 · Recurrent/ Metastatic Olfactory Neuroblastoma	Phase 2	Recruiting	National Cancer Center Hospital East	Japan
Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma NCT07152678 · ClinicalTrials.gov ↗ · Esophageal Cancer, Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	National Taiwan University Hospital	Taiwan
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure NCT07219459 · Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound	Phase 2	Recruiting	CatalYm GmbH	UK, USA, Germany, France, Spain, Italy
Neo-adjuvant Immunotherapy in Patients With Localized Melanoma NCT07230613 · ClinicalTrials.gov ↗ · Cutaneous Melanoma, Stage III, Mucosal Melanoma	Phase 2	Recruiting	UNICANCER	France
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC NCT07246863 · ClinicalTrials.gov ↗ · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor	Phase 2	Recruiting	CatalYm GmbH	USA, Germany, Spain, Italy, Poland, Switzerland
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC NCT07398937 · ClinicalTrials.gov ↗ · Resectable Stage II-IIIa Squamous NSCLC	Phase 2	Recruiting	Fudan University	China
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) NCT07432295 · Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 2	Recruiting	I-Mab Biopharma US Limited	USA, China, Japan, Egypt
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer NCT07527858 · Advanced Microsatellite Stable Colorectal Cancer	Phase 2	Recruiting	Gilead Sciences	USA, Spain, South Korea, Australia, Israel
Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma NCT07529873 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck (SCCHN)	Phase 2	Recruiting	Groupe Oncologie Radiotherapie Tete et Cou	France
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas NCT07546812 · HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma	Phase 2	Recruiting	Gilead Sciences	USA, France, Spain, South Korea, Australia
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer NCT07645118 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	Dr. Te Vuong	Canada
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer NCT07884877 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy	Phase 2	Recruiting	Samsung Medical Center	South Korea
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors NCT02813135 · ClinicalTrials.gov ↗ · Pediatric Cancer	Phase 1/2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France, Spain, Italy, Netherlands, Denmark
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion NCT03685890 · ClinicalTrials.gov ↗ · Melanoma, In-Transit Metastasis	Phase 1/2	Recruiting	Vastra Gotaland Region	Netherlands, Sweden
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors NCT03686124 · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult	Phase 1/2	Recruiting	Immatics US, Inc	USA, Germany
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer	Phase 1/2	Recruiting	Bristol-Myers Squibb	USA, Germany, Spain, Italy, Canada, Japan, Australia, Israel
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI NCT04954599 · ClinicalTrials.gov ↗ · Unspecified Adult Solid Tumor, Protocol Specific	Phase 1/2	Recruiting	Maastricht University Medical Center	Spain, Netherlands, Belgium
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy NCT05187429 · ClinicalTrials.gov ↗ · HIV I Infection	Phase 1/2	Recruiting	University of Melbourne	Singapore, Australia
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626 · Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma	Phase 1/2	Recruiting	Aulos Bioscience, Inc	USA, Australia
A Study of TRK-950 in Patients With Advanced Solid Tumors NCT05423262 · ClinicalTrials.gov ↗ · Solid Tumor, Melanoma	Phase 1/2	Recruiting	Toray Industries, Inc	Japan
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors NCT05533697 · Advanced Solid Tumors	Phase 1/2	Recruiting	ModernaTX, Inc	UK, USA, Germany, Spain, Italy, Poland, Australia
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors NCT05584670 · Solid Tumor	Phase 1/2	Recruiting	Sanofi	USA, Spain, Netherlands, Japan, Israel
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma NCT05655312 · Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV	Phase 1/2	Recruiting	Perspective Therapeutics	USA
First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) NCT05749900 · ClinicalTrials.gov ↗ · HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer	Phase 1/2	Recruiting	Yonsei University	South Korea
FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 · ClinicalTrials.gov ↗ · Cancer, Colorectal Cancer, Solid Tumor	Phase 1/2	Recruiting	Parabilis Medicines, Inc	USA, Australia
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379 · ClinicalTrials.gov ↗ · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult	Phase 1/2	Recruiting	Neonc Technologies, Inc	USA
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases NCT06163820 · ClinicalTrials.gov ↗ · Melanoma Brain Metastases	Phase 1/2	Recruiting	Melanoma and Skin Cancer Trials Limited	Australia
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma NCT06240143 · ClinicalTrials.gov ↗ · Melanoma	Phase 1/2	Recruiting	The Netherlands Cancer Institute	Netherlands
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 · Advanced Cancer, Advanced Solid Tumor, Melanoma	Phase 1/2	Recruiting	7 Hills Pharma, LLC	USA
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors NCT06618287 · Lung Cancer, Breast Cancer	Phase 1/2	Recruiting	Bristol-Myers Squibb	UK, USA, France, Spain, Italy, Netherlands, Canada, Taiwan, Australia
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies NCT07276373 · Neoplasms	Phase 1/2	Recruiting	Corcept Therapeutics	USA
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO NCT03816345 · ClinicalTrials.gov ↗ · Autoimmune Disease, Crohn Disease, Dermatomyositis	Phase 1	Recruiting	National Cancer Institute (NCI)	Canada
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760 · Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 1	Recruiting	Memgen, Inc	USA
Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) NCT05112549 · ClinicalTrials.gov ↗ · Leptomeningeal Disease	Phase 1	Recruiting	University Hospital Tuebingen	Germany
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors NCT05176483 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)	Phase 1	Recruiting	Exelixis	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Australia, Israel
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors NCT06764771 · Advanced Malignant Tumors	Phase 1	Recruiting	Bristol-Myers Squibb	USA, Canada, Australia
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors NCT07334119 · ClinicalTrials.gov ↗ · HER2-Expressing Solid Tumors	Phase 1	Recruiting	Myeloid Therapeutics	Australia
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707 · ClinicalTrials.gov ↗ · CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma	Phase 1	Recruiting	Hefei TG ImmunoPharma Co., Ltd	China
Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC) NCT07653503 · ClinicalTrials.gov ↗ · Cervical Carcinoma	Phase 1	Recruiting	University Medical Center Groningen	Netherlands
The Immune Assessment of PD-1 Antibody Therapy in Tumor NCT06693440 · ClinicalTrials.gov ↗ · Efficacy, Team, Adverse Event	Observational	Recruiting	Quanli Gao	China
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. NCT06724159 · Genitourinary Cancers	Observational	Recruiting	Spanish Oncology Genito-Urinary Group	Spain
Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen NCT07061379 · ClinicalTrials.gov ↗ · PROMs	Observational	Recruiting	IRCCS San Raffaele	Italy
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. NCT07092670 · ClinicalTrials.gov ↗ · Melanoma, Fertility	Observational	Recruiting	Intergruppo Melanoma Italiano	Italy
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment NCT07147101 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC)	Observational	Recruiting	Fudan University	China
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) NCT07394062 · ClinicalTrials.gov ↗ · Nonsmall Cell Lung Cancer, Stage IV, Metastatic Nonsmall Cell Lung Cancer	Observational	Recruiting	Gazi University	Turkey
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer NCT07419932 · ClinicalTrials.gov ↗ · Thyroid Cancer, Thyroid Neoplasms	Observational	Recruiting	Fujian Medical University	China
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial NCT05652673 · ClinicalTrials.gov ↗ · Melanoma Stage IV, Melanoma Stage III, Immunotherapy	Not applicable	Recruiting	Erasmus Medical Center	Netherlands
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) NCT06519682 · ClinicalTrials.gov ↗ · High Grade Glioma, Replication Repair Deficient	Not applicable	Recruiting	Daniel Morgenstern	Canada
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India NCT07459543 · Unresectable Melanoma, Metastatic Melanoma	Phase 4	Not yet open	Bristol-Myers Squibb	India
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. NCT07338981 · ClinicalTrials.gov ↗ · Advanced Kidney Cancer	Phase 3	Not yet open	Guliz Ozgun	Canada
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma NCT07815574 · Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma	Phase 3	Not yet open	Scancell Ltd	UK, USA
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer NCT07403877 · ClinicalTrials.gov ↗ · Colorectal Cancer (MSI-H)	Phase 2	Not yet open	Fudan University	China
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease NCT07420439 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)	Phase 2	Not yet open	Intergroupe Francophone de Cancerologie Thoracique	France
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC NCT07494435 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC), Renal Cell Cancer	Phase 2	Not yet open	Zhejiang Haichang Biotech Co., Ltd	China
Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma NCT07514767 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC)	Phase 2	Not yet open	Prof. Lars Olaf Cardell	Sweden
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer NCT07877194 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma, Clear Cell	Phase 2	Not yet open	Summit Therapeutics	USA, China
An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC NCT07902258 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor, Neoadjuvant Therapy	Phase 2	Not yet open	National Taiwan University Hospital	Taiwan
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC NCT07919717 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients NCT07679841 · ClinicalTrials.gov ↗ · Vulvar Squamous Cell Carcinoma	Phase 1/2	Not yet open	Centre Leon Berard	France
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) NCT07848295 · Clear Cell Renal Cell Carcinoma (ccRCC)	Phase 1	Not yet open	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	USA, Germany, France, Spain, Italy, Netherlands, Belgium
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study NCT07620574 · Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET)	Phase 3	By invitation	Exelixis	USA
Development and Analysis of a Stool Bank for Cancer Patients NCT04291755 · Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal	Observational	By invitation	Persephone Biosciences	USA
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites NCT05745233 · ClinicalTrials.gov ↗ · Malignant Ascites	Not applicable	By invitation	China Medical University Hospital	China, Taiwan
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma NCT02224781 · ClinicalTrials.gov ↗ · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) NCT02595944 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers NCT02785952 · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7	Phase 3	Active, closed	SWOG Cancer Research Network	Canada, Mexico, Israel
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy NCT03055013 · ClinicalTrials.gov ↗ · Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer NCT03233711 · ClinicalTrials.gov ↗ · Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation NCT03383458 · Hepatocellular Carcinoma, Liver Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Austria, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy NCT03522246 · Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer	Phase 3	Active, closed	pharmaand GmbH	Ireland, UK, USA, China, Germany, Spain, Italy, Belgium, Sweden, Denmark, Poland, Czechia, Turkey, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck NCT03576417 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 3	Active, closed	Groupe Oncologie Radiotherapie Tete et Cou	France
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study NCT03793166 · ClinicalTrials.gov ↗ · Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway, Mexico
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer NCT03811015 · ClinicalTrials.gov ↗ · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer NCT03873402 · Renal Cell Carcinoma	Phase 3	Active, closed	Bristol-Myers Squibb	USA, France, Spain, Italy, Poland, Austria, Czechia, Portugal, Mexico
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma NCT03907488 · ClinicalTrials.gov ↗ · Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma NCT03937219 · Renal Cell Carcinoma	Phase 3	Active, closed	Exelixis	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Canada, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) NCT04008030 · Metastatic Colorectal Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Austria, Czechia, Norway, Turkey, Canada, Brazil, Japan, Australia
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer NCT04025879 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Canada, Brazil, Mexico, Japan, Taiwan, Australia
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma NCT04099251 · Melanoma	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Australia
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma NCT04309409 · ClinicalTrials.gov ↗ · Malignant Melanoma Stage II	Phase 3	Active, closed	University Hospital, Essen	Germany
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy NCT04564157 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Adjuvant Chemotherapy	Phase 3	Active, closed	Fundación GECP	Spain
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy NCT04637594 · ClinicalTrials.gov ↗ · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma NCT04674683 · Unresectable or Metastatic Melanoma, Progressive Brain Metastasis	Phase 3	Active, closed	HUYABIO International, LLC	UK, USA, Germany, France, Spain, Italy, Belgium, Austria, Czechia, Brazil, Japan, South Korea, Singapore, Australia
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma NCT04759586 · ClinicalTrials.gov ↗ · Primary Mediastinal Large B-Cell Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread NCT04810078 · Clear Cell Renal Cell Carcinoma	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, USA, France, Spain, Italy, Poland, Czechia, Portugal, Turkey, Brazil, Mexico
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma NCT04949113 · ClinicalTrials.gov ↗ · Malignant Melanoma Stage III	Phase 3	Active, closed	The Netherlands Cancer Institute	Netherlands, Australia
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) NCT05144854 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Active, closed	Ono Pharmaceutical Co., Ltd	China, Japan, South Korea, Taiwan
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma NCT05625399 · Melanoma	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Australia, Israel
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma NCT05678673 · Non-Clear Cell Renal Cell Carcinoma	Phase 3	Active, closed	Exelixis	UK, USA, Germany, France, Spain, Italy, Netherlands, Poland, Czechia, Turkey, Brazil, South Korea, Singapore, Australia
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma NCT06054555 · Melanoma	Phase 3	Active, closed	Amgen	USA, China, Germany, France, Spain, Italy, Netherlands, Czechia, Portugal, Turkey, Canada, Mexico, South Korea, Taiwan, Israel
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma NCT06097728 · Unresectable Pleural Mesothelioma	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer NCT06632327 · ClinicalTrials.gov ↗ · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma NCT02339571 · Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma NCT03470922 · Melanoma	Phase 2/3	Active, closed	Bristol-Myers Squibb	UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Norway, Canada, Brazil, Mexico, Australia, Israel
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer NCT03952585 · Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma NCT05987332 · Metastatic Uveal Melanoma	Phase 2/3	Active, closed	IDEAYA Biosciences	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Canada, Australia, Israel
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer NCT02257528 · ClinicalTrials.gov ↗ · Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC NCT02259621 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Active, closed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Canada
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial NCT02275533 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer NCT02314169 · ClinicalTrials.gov ↗ · Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases NCT02374242 · ClinicalTrials.gov ↗ · Melanoma, Brain Metastases	Phase 2	Active, closed	Melanoma Institute Australia	Australia
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) NCT02465060 · ClinicalTrials.gov ↗ · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel, Egypt
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 · ClinicalTrials.gov ↗ · Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib NCT02873962 · ClinicalTrials.gov ↗ · Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma NCT03097939 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	National Cancer Centre, Singapore	Singapore
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) NCT03134118 · ClinicalTrials.gov ↗ · Thymoma Type B3, Thymic Carcinoma	Phase 2	Active, closed	European Organisation for Research and Treatment of Cancer - EORTC	France, Spain, Netherlands, Belgium, Switzerland
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) NCT03203473 · ClinicalTrials.gov ↗ · Renal Cancer	Phase 2	Active, closed	Toni Choueiri, MD	Israel
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors NCT03228667 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma	Phase 2	Active, closed	ImmunityBio, Inc	USA
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib NCT03235245 · ClinicalTrials.gov ↗ · Unresectable Stage III Melanoma, Stage IV Melanoma	Phase 2	Active, closed	European Organisation for Research and Treatment of Cancer - EORTC	Germany, France, Spain, Italy, Netherlands, Denmark, Poland
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors NCT03333616 · ClinicalTrials.gov ↗ · Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab NCT03350126 · ClinicalTrials.gov ↗ · Metastatic Cancer Colorectal	Phase 2	Active, closed	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer NCT03367741 · ClinicalTrials.gov ↗ · Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer NCT03505320 · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer	Phase 2	Active, closed	Astellas Pharma Global Development, Inc	USA, France, Italy, Japan, South Korea, Taiwan
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer NCT03563248 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Active, closed	Massachusetts General Hospital	Israel
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) NCT03595124 · ClinicalTrials.gov ↗ · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Egypt
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer NCT03637543 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 2	Active, closed	Beth Israel Deaconess Medical Center	Israel
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) NCT03703050 · ClinicalTrials.gov ↗ · Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma	Phase 2	Active, closed	Gustave Roussy, Cancer Campus, Grand Paris	France, Denmark
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma NCT03712202 · ClinicalTrials.gov ↗ · Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma	Phase 2	Active, closed	City of Hope Medical Center	Israel
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) NCT03767348 · Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC)	Phase 2	Active, closed	Replimune, Inc	UK, USA, Germany, France, Spain
NADIM II: Neo-Adjuvant Immunotherapy NCT03838159 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) NCT03865082 · Solid Tumor	Phase 2	Active, closed	Idera Pharmaceuticals, Inc	USA
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients NCT03921684 · Rectal Cancer	Phase 2	Active, closed	Baruch Brenner	Israel
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. NCT04006262 · ClinicalTrials.gov ↗ · Localized Oesogastric Adenocarcimona, MSI and or dMMR	Phase 2	Active, closed	GERCOR - Multidisciplinary Oncology Cooperative Group	France
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China NCT04015778 · Non Small Cell Lung Cancer	Phase 2	Active, closed	Guangdong Association of Clinical Trials	China
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors NCT04079712 · ClinicalTrials.gov ↗ · Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors NCT04126070 · ClinicalTrials.gov ↗ · Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma	Phase 2	Active, closed	Xiao X. Wei, MD	Israel
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM NCT04195139 · ClinicalTrials.gov ↗ · Glioblastoma Multiforme	Phase 2	Active, closed	University of Sydney	Australia
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. NCT04229459 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Baruch Brenner	Israel
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma NCT04300244 · ClinicalTrials.gov ↗ · Cancer, Cancer, Lung, Cancer of Lung	Phase 2	Active, closed	Åslaug Helland	Spain, Sweden, Denmark, Norway, Australia
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer NCT04310007 · ClinicalTrials.gov ↗ · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer NCT04361162 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Metastatic Pancreatic Cancer	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC NCT04413123 · ClinicalTrials.gov ↗ · Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma	Phase 2	Active, closed	Bradley A. McGregor, MD	Israel
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial NCT04462406 · ClinicalTrials.gov ↗ · Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer NCT04503694 · ClinicalTrials.gov ↗ · Rectal Cancer Stage II, Rectal Cancer Stage III	Phase 2	Active, closed	Jules Bordet Institute	Belgium
Nivolumab+Ipilimumab+RT in MSS mCRC NCT04575922 · ClinicalTrials.gov ↗ · Metastatic Microsatellite Stable Colorectal Cancer	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC NCT04699721 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB	Phase 2	Active, closed	Xiangya Hospital of Central South University	China
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. NCT04730544 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, MSI-H Colorectal Cancer	Phase 2	Active, closed	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) NCT04884282 · ClinicalTrials.gov ↗ · Metastatic Non Small Cell Lung Cancer	Phase 2	Active, closed	Fondazione Ricerca Traslazionale	France, Spain, Italy
Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma NCT04910347 · ClinicalTrials.gov ↗ · Locally Advanced Nasopharyngeal Carcinoma	Phase 2	Active, closed	Yonsei University	South Korea
Combination Immunotherapy in Rare Cancers Under InvesTigation NCT04969887 · Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm	Phase 2	Active, closed	Olivia Newton-John Cancer Research Institute	Australia
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases NCT05012254 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery NCT05111574 · ClinicalTrials.gov ↗ · Anal Melanoma, Bladder Melanoma, Cervical Melanoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC NCT05200988 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Bladder Cancer	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy NCT05215470 · ClinicalTrials.gov ↗ · Renal Cancer Metastatic	Phase 2	Active, closed	Hospital das Clínicas de Ribeirão Preto	Brazil
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation NCT05308446 · ClinicalTrials.gov ↗ · Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Egypt
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer NCT05476796 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	UNICANCER	France
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study NCT05491616 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Active, closed	Erasmus Medical Center	Netherlands
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin NCT05504252 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma	Phase 2	Active, closed	University Hospital, Akershus	Norway
Study of Novel Treatment Combinations in Patients With Lung Cancer NCT05633667 · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Turkey, Brazil, South Korea, Taiwan, Israel
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors NCT05684276 · ClinicalTrials.gov ↗ · NSCLC, Pancoast Tumor	Phase 2	Active, closed	Fundación GECP	Spain
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) NCT05696548 · ClinicalTrials.gov ↗ · Anaplastic Thyroid Cancer	Phase 2	Active, closed	National Cancer Center Hospital East	Japan
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. NCT05788081 · ClinicalTrials.gov ↗ · Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV	Phase 2	Active, closed	Olivia Newton-John Cancer Research Institute	Australia
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma NCT05836571 · ClinicalTrials.gov ↗ · Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma	Phase 2	Active, closed	National Cancer Institute LAO	Canada
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations NCT06101134 · Melanoma	Phase 2	Active, closed	Bristol-Myers Squibb	USA, Spain, Italy
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab NCT06237920 · ClinicalTrials.gov ↗ · Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) NCT06256328 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	Ono Pharmaceutical Co., Ltd	China, Japan, South Korea, Taiwan
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) NCT06534983 · Muscle-invasive Urothelial Carcinoma	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA, Germany, Spain, Italy, Sweden, Denmark, Poland, Norway, Canada, South Korea, Taiwan, Australia
Agnostic Therapy in Rare Solid Tumors NCT06638931 · ClinicalTrials.gov ↗ · Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma	Phase 2	Active, closed	Instituto do Cancer do Estado de São Paulo	Brazil
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) NCT06946797 · Non-Small Cell Lung Cancer	Phase 2	Active, closed	Bristol-Myers Squibb	USA, France, Italy, Poland, Brazil
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT01896999 · ClinicalTrials.gov ↗ · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma	Phase 1/2	Active, closed	National Cancer Institute (NCI)	Mexico
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) NCT03033914 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma	Phase 1/2	Active, closed	Memorial Sloan Kettering Cancer Center	Canada
A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. NCT03233152 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 1/2	Active, closed	Universitair Ziekenhuis Brussel	Belgium
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) NCT03544736 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 1/2	Active, closed	Oslo University Hospital	Norway
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors NCT03647163 · Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma	Phase 1/2	Active, closed	Vyriad, Inc	USA
Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic Nivolumab NCT03707808 · ClinicalTrials.gov ↗ · Solid Tumor, Metastases to Soft Tissue	Phase 1/2	Active, closed	Universitair Ziekenhuis Brussel	Belgium
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer NCT03907852 · ClinicalTrials.gov ↗ · Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura	Phase 1/2	Active, closed	TCR2 Therapeutics	USA, Canada
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor NCT04078295 · ClinicalTrials.gov ↗ · Solid Neoplasms	Phase 1/2	Active, closed	Eisai Co., Ltd	Japan
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression NCT04180371 · Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer	Phase 1/2	Active, closed	BicycleTx Limited	UK, USA, Spain, Belgium, South Korea
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN NCT04317105 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm	Phase 1/2	Active, closed	National Cancer Institute (NCI)	Canada
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors NCT04396821 · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd	USA
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors NCT04495296 · ClinicalTrials.gov ↗ · Advanced Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd	China
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) NCT04725474 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 1/2	Active, closed	CatalYm GmbH	Germany, Spain, Switzerland
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression NCT05163041 · Advanced Solid Tumor	Phase 1/2	Active, closed	BicycleTx Limited	UK, USA
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors NCT05888831 · Advanced Solid Tumors	Phase 1/2	Active, closed	Bristol-Myers Squibb	USA, France, Spain, Italy, Netherlands, Belgium
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors NCT02099058 · Advanced Solid Tumors Cancer	Phase 1	Active, closed	AbbVie	USA, China, France, Italy, Netherlands, Belgium, Japan, South Korea, Taiwan
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) NCT02293980 · ClinicalTrials.gov ↗ · ccRCC, RCC, Kidney Cancer	Phase 1	Active, closed	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	USA, Israel
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer NCT02393625 · ClinicalTrials.gov ↗ · ALK-positive NSCLC	Phase 1	Active, closed	Novartis Pharmaceuticals	USA, Spain, Italy, Belgium, Canada, Singapore, Australia
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) NCT02817633 · Neoplasms	Phase 1	Active, closed	Tesaro, Inc	USA, Spain, South Korea, Egypt
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors NCT03155061 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NCT03589339 · Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour	Phase 1	Active, closed	Nanobiotix	USA
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer NCT03816358 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8	Phase 1	Active, closed	National Cancer Institute (NCI)	Canada
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults NCT04323046 · ClinicalTrials.gov ↗ · Glioblastoma, Malignant Glioma, Recurrent Glioblastoma	Phase 1	Active, closed	Sabine Mueller, MD, PhD	Australia
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors NCT04336241 · Cancer	Phase 1	Active, closed	Replimune, Inc	UK, Spain
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours NCT04735978 · Advanced Solid Tumor	Phase 1	Active, closed	Replimune, Inc	UK, USA, France, Spain
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. NCT04835805 · Melanoma	Phase 1	Active, closed	Genentech, Inc	USA, Germany, Canada, South Korea, Australia
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy NCT05352828 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent	Phase 1	Active, closed	Tessa Therapeutics	USA
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors NCT05704985 · Cancer, Solid Tumor, Colorectal Cancer	Phase 1	Active, closed	DEKA Biosciences	USA
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma NCT06377111 · ClinicalTrials.gov ↗ · Melanoma (Skin)	Phase 1	Active, closed	University Health Network, Toronto	Canada
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer NCT06532331 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer NCT06532344 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer NCT06540261 · ClinicalTrials.gov ↗ · Unresectable Colorectal Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors NCT06544655 · Advanced Solid Tumors	Phase 1	Active, closed	Bristol-Myers Squibb	USA, Canada, Australia
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer NCT06547385 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors NCT03695952 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Biliary Tract Cancer	Observational	Active, closed	Asan Medical Center	South Korea
A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06487156 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Observational	Active, closed	Bristol-Myers Squibb	Italy
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France NCT06504615 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma (EAC)	Observational	Active, closed	Bristol-Myers Squibb	France
Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice NCT07663786 · ClinicalTrials.gov ↗ · Esophageal Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Observational	Active, closed	Bristol-Myers Squibb	Netherlands
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada NCT07718139 · Non-Small Cell Lung Cancer	Observational	Active, closed	Bristol-Myers Squibb	UK
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) NCT02194738 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8	Not applicable	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Nivolumab in the EU trials register (CTIS)

13 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Nivolumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER 2025-524263-21-01 · Neoplasms	Phase 3	Ongoing	F. Hoffmann-La Roche AG	Ireland + 10 more
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations” 2026-525268-16-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Universita' Degli Studi Di Torino	Italy
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04). 2025-525030-57-00 · Neoplasms	Phase 3	Ongoing	AstraZeneca AB	Italy, Poland, Spain + 2 more
Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high 2026-525445-73-00 · Neoplasms	Phase 2	Authorised	UZ Brussel	Belgium
Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial. 2025-523903-31-00 · Neoplasms	Phase 3	Authorised	Fondazione IRCCS Istituto Nazionale Dei Tumori	Italy
Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma 2026-526821-16-00 · Neoplasms	Phase 1	Authorised	Karolinska University Hospital	Sweden
Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors 2025-524125-40-01 · Neoplasms	Phase 2	Authorised	Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets	Italy
Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT). 2025-523617-29-01 · Neoplasms	Phase 2	Authorised	Amsterdam UMC Stichting	Netherlands
Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial) 2025-523725-17-00 · Immune System Diseases	Phase 2	Ongoing	Region Midtjylland	Sweden, Norway, Denmark + 1 more
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours 2025-524620-22-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Orion Corporation	Finland, Denmark, Spain + 1 more
A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer) 2025-522944-41-00 · CTIS ↗ · Not possible to specify	Phase 1	Authorised	Pathios Therapeutics Limited	France, Spain
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma 2023-508784-68-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Replimune Inc	Germany, Italy, France + 2 more
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study) 2025-521562-95-00 · CTIS ↗ · Musculoskeletal Diseases	Phase 3	Ongoing	Mabxience Research S.L	Italy, Spain, Slovakia + 4 more

Nivolumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

3 single-substance products containing Nivolumab on the HPRA medicines list.

OPDIVO 10 mg/mL concentrate for solution for infusionBristol-Myers Squibb Pharma EEIG · EU/1/15/1014/001-004
OPDIVO 300 mg solution for injectionBristol-Myers Squibb Pharma EEIG · EU/1/15/1014/006
OPDIVO 600 mg solution for injectionBristol-Myers Squibb Pharma EEIG · EU/1/15/1014/005

All 3 Irish products →

Supply shortages

No entry for Nivolumab in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Nivolumab

429 conditions

Melanoma13 Solid Tumor10 Cancer8 Non-Small Cell Lung Cancer8 Gastric Cancer8 Non Small Cell Lung Cancer7 Advanced Cancer7 Colorectal Cancer6Metastatic Renal Cell Carcinoma4Non-small Cell Lung Cancer4 Advanced Solid Tumor4 Hepatocellular Carcinoma4

All 429 conditions

Condition (as registered)	Trials
Melanoma	13
Solid Tumor	10
Cancer	8
Non-Small Cell Lung Cancer	8
Gastric Cancer	8
Non Small Cell Lung Cancer	7
Advanced Cancer	7
Colorectal Cancer	6
Metastatic Renal Cell Carcinoma	4
Non-small Cell Lung Cancer	4
Advanced Solid Tumor	4
Hepatocellular Carcinoma	4
Advanced Solid Tumors	4
Esophageal Cancer	4
Advanced Melanoma	4
Metastatic Cancer	4
Metastatic Melanoma	4
Gastric Adenocarcinoma	4
Metastatic Colorectal Cancer	3
Clear Cell Renal Cell Carcinoma	3
Cutaneous Melanoma	3
Lung Cancer	3
Mucosal Melanoma	3
Renal Cell Carcinoma (RCC)	3
Renal Cell Carcinoma	3
Immunotherapy	3
Pancreatic Cancer	3
Melanoma Stage IV	3
Esophageal Adenocarcinoma	3
Neoplasms	3
Clinical Stage III Cutaneous Melanoma AJCC v8	3
Clinical Stage IV Cutaneous Melanoma AJCC v8	3
Metastatic Pancreatic Cancer	3
Stage III Renal Cell Cancer AJCC v8	2
Stage IV Renal Cell Cancer AJCC v8	2
Carcinoma, Non-Small-Cell Lung	2
Fallopian Tube Cancer	2
Metastatic Uveal Melanoma	2
Gastroesophageal Junction Adenocarcinoma	2
Ovarian Cancer	2
Breast Cancer	2
Locally Advanced Solid Tumor	2
Melanoma Stage III	2
Cervical Cancer	2
Brain Metastases, Adult	2
Kidney Cancer	2
Solid Tumor, Adult	2
Urothelial Carcinoma	2
Head and Neck Squamous Cell Carcinoma	2
Mesothelioma	2
Mesotheliomas Pleural	2
Hepatocellular Carcinoma (HCC)	2
Hepato Cellular Carcinoma (HCC)	2
Renal Cell Cancer	2
Melanoma (Skin Cancer)	2
Nasopharyngeal Carcinoma	2
Nasopharyngeal Cancer	2
Gastro-esophageal Junction Adenocarcinoma	2
Malignant Melanoma Stage III	2
Glioblastoma	2
Stage IB Lung Non-Small Cell Carcinoma AJCC v7	2
Stage II Lung Non-Small Cell Cancer AJCC v7	2
Advanced Malignant Solid Neoplasm	2
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	2
Hodgkin Lymphoma	2
Stage IV Nasopharyngeal Carcinoma AJCC v8	2
Advanced Esophageal Adenocarcinoma	2
Advanced Gastric Adenocarcinoma	2
Advanced Gastroesophageal Junction Adenocarcinoma	2
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	2
Esophageal Squamous Cell Carcinoma	2
Unresectable Renal Cell Carcinoma	1
Epithelial Ovarian Cancer	1
Primary Peritoneal	1
Newly Diagnosed	1
Non-Small Cell Lung Cancer (NSCLC)	1
Microsatellite Instability-High (MSI-H)	1
Non-melanoma Skin Cancer (NMSC)	1
Unresectable Pleural Mesothelioma	1
Extensive-Stage Small Cell Lung Cancer	1
Advanced or Metastatic Non-Small-Cell Lung Cancer	1
Resectable Non-Small-Cell Lung Cancer	1
High-risk Muscle Invasive Urothelial Carcinoma	1
Melanoma, Cutaneous Malignant	1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)	1
Urothelial Carcinoma (UC)	1
Liver Cancer	1
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma	1
Muscle-invasive Urothelial Carcinoma	1
Unresectable or Metastatic Hepatocellular Carcinoma	1
Child-Pugh A Hepatocellular Carcinoma	1
Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound	1
Advanced Solid Tumor Historically Known for High EphA2 Expression	1
Urothelial Cancer	1
Unresectable or Metastatic Melanoma	1
Progressive Brain Metastasis	1
Solid Tumors	1
Non-Clear Cell Renal Cell Carcinoma	1
Von Hippel-Lindau Disease	1
Malignant Neoplasms	1
Pancreatic Neuroendocrine Tumors (pNET)	1
Extra-Pancreatic NET (epNET)	1
Neuroendocrine Carcinoma	1
Radiotherapy	1
Microsatellite Instability-High Solid Malignant Tumour	1
Metastasis From Malignant Tumor of Liver	1
Gastroesophageal-junction Cancer	1
Pancreas Cancer	1
ALK-positive NSCLC	1
Recurrent Melanoma (Skin)	1
Gastric / Gastroesophageal Junction Adenocarcinoma	1
HER2-negative	1
Gastroesophageal Junction	1
Metastatic Non-Squamous Non-Small Cell Lung Cancer	1
Adult Solid Tumor	1
Brain Tumor	1
Renal Cell Carcinoma, Clear Cell	1
Gastric/Gastroesophageal Junction Adenocarcinoma	1
Microsatellite Stable Colorectal Cancer	1
Non-Small-Cell Lung Cancer	1
Advanced Malignant Tumors	1
Diffuse Astrocytoma, IDH-Mutant	1
Glioblastoma, IDH-wildtype	1
ccRCC	1
RCC	1
Refractory Cancer	1
Recurrent Cancer	1
Classical Hodgkin Lymphoma	1
Hodgkin Disease Refractory	1
Hodgkin Disease Recurrent	1
Carcinoma, Colorectal	1
Pharmacokinetics of Zolbetuximab	1
Gastro-esophageal Junction (GEJ) Cancer	1
Pharmacokinetics of Oxaliplatin	1
Small Cell Lung Cancer	1
Metastasis	1
Mesothelioma, Malignant	1
Mesothelioma; Pleura	1
Clear Cell Renal Cell Carcinoma (ccRCC)	1
Advanced Microsatellite Stable Colorectal Cancer	1
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma	1
Metastatic Gastric Cancer	1
Gastroesophageal Junction Cancer	1
Advanced Solid Tumors Cancer	1
Unresectable Melanoma	1
Recurrent Hepatocellular Cancer	1
Colorectal Cancer (MSI-H)	1
Thyroid Cancer	1
Thyroid Neoplasms	1
Non-small Cell Lung Cancer Stage II	1
Non-small Cell Lung Cancer Stage ⅢA	1
Non-small Cell Lung Cancer Stage IIIB	1
Resectable Stage II-IIIa Squamous NSCLC	1
Malignant Ascites	1
CRC (Colorectal Cancer)	1
HCC - Hepatocellular Carcinoma	1
NSCLC (Non-small Cell Lung Cancer)	1
Advanced Hepatocellular Carcinoma (HCC)	1
Efficacy, Team	1
Adverse Event	1
Malignant Neoplasms of Digestive Organs	1
Unresectable Stage III Melanoma	1
Stage IV Melanoma	1
Nasopharyngeal Neoplasms	1
Nasopharynx Cancer	1
Malignant Melanoma Stage II	1
Leptomeningeal Disease	1
Colon Cancer Stage II	1
Colon Cancer Stage III	1
Localized Oesogastric Adenocarcimona	1
MSI and or dMMR	1
Metastatic Kidney Cancer	1
Metastatic Kidney Carcinoma	1
Vulvar Squamous Cell Carcinoma	1
Advanced Non Small Cell Lung Cancer	1
MET Exon 14 Mutation	1
Metastatic Gastroesophageal Adenocarcinoma	1
DPD Deficiency	1
Non Small Cell Lung Cancer Metastatic	1
Interstitial Lung Disease (ILD)	1
Esophageal Adenocarcinoma (EAC)	1
Esophageal Squamous Cell Carcinoma (ESCC)	1
Metastatic Non Small Cell Lung Cancer	1
Cutaneous Melanoma, Stage III	1
Colorectal Cancer Metastatic	1
MSI-H Colorectal Cancer	1
Squamous Cell Carcinoma of Head and Neck (SCCHN)	1
MSI-H	1
Pediatric Cancer	1
Squamous Cell Carcinoma of Head and Neck	1
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma	1
Esophagus Adenocarcinoma	1
Thymoma Type B3	1
Thymic Carcinoma	1
Malignant Pleural Mesothelioma	1
Metastatic Cancer Colorectal	1
Cancer, Lung	1
Cancer of Lung	1
NSCLC	1
Pancoast Tumor	1
Unspecified Adult Solid Tumor, Protocol Specific	1
Adjuvant Chemotherapy	1
Genitourinary Cancers	1
Non-small Cell Lung Cancer (NSCLC)	1
Fertility	1
PROMs	1
Resectable Colorectal Carcinoma	1
In-Transit Metastasis	1
Cutaneous Squamous Cell Carcinoma (CSCC)	1
Cutaneous Squamous Cell Cancer	1
Cutaneous Squamous Cell Carcinoma of the Head and Neck	1
Cutaneous Squamous Cell Carcinoma	1
Urologic Neoplasms	1
Urogenital Neoplasms	1
Neoplasms by Site	1
Cervical Carcinoma	1
Toxicity, Drug	1
Bladder Cancer	1
Oncology	1
Infusion Reaction	1
Metastatic Breast Cancer	1
Tumors	1
Neoplasm	1
Neoplasia	1
Colon Carcinoma	1
Metastases to Soft Tissue	1
Rectal Cancer Stage II	1
Rectal Cancer Stage III	1
Oral Squamous Cell Carcinoma (OSCC)	1
Uveal Melanoma	1
Liver Metastases	1
High-risk Melanoma	1
Cancer of Rectum	1
Malignant Melanoma	1
Squamous Cell Carcinoma of the Skin	1
Colorectal Adenocarcinoma	1
Mucinous Adenocarcinoma	1
Signet Ring Cell Adenocarcinoma	1
Metastatic Malignant Neoplasm in the Bone	1
Metastatic Malignant Neoplasm in the Lymph Nodes	1
Metastatic Malignant Neoplasm in the Soft Tissue	1
Melanoma Stage Iv	1
Stage IIA Lung Cancer AJCC v8	1
Stage IIB Lung Cancer AJCC v8	1
Advanced Lymphoma	1
Bladder Carcinoma	1
Breast Carcinoma	1
Nonsmall Cell Lung Cancer, Stage IV	1
Metastatic Nonsmall Cell Lung Cancer	1
Melanoma (Skin)	1
Lymphoma, Non-Hodgkin	1
Multiple Myeloma	1
Down Syndrome	1
Recurrent B Acute Lymphoblastic Leukemia	1
Muscle Invasive Bladder Urothelial Carcinoma	1
Muscle Invasive Renal Pelvis Urothelial Carcinoma	1
Muscle Invasive Ureter Urothelial Carcinoma	1
Muscle Invasive Urethral Urothelial Carcinoma	1
Sarcomatoid Renal Cell Carcinoma	1
Stage II Renal Cell Cancer AJCC v7	1
Stage III Renal Cell Cancer AJCC v7	1
Locally Advanced Rectal Cancer	1
Anal Canal Squamous Cell Carcinoma	1
Metastatic Anal Canal Carcinoma	1
Stage IV Anal Cancer AJCC v8	1
Primary Mediastinal Large B-Cell Lymphoma	1
Basaloid Squamous Cell Carcinoma	1
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	1
Oropharyngeal Squamous Cell Carcinoma	1
Autoimmune Disease	1
Crohn Disease	1
Dermatomyositis	1
Hematopoietic and Lymphoid Cell Neoplasm	1
Advanced Kidney Cancer	1
Metastatic Large Cell Neuroendocrine Carcinoma	1
Metastatic Neuroendocrine Carcinoma	1
Metastatic Neuroendocrine Neoplasm	1
Metastatic Small Cell Neuroendocrine Carcinoma	1
Acute Myeloid Leukemia	1
Locally Advanced Extraskeletal Myxoid Chondrosarcoma	1
Locally Advanced Leiomyosarcoma	1
Locally Advanced Liposarcoma	1
Locally Advanced Undifferentiated Pleomorphic Sarcoma	1
Metastatic Nasopharyngeal Carcinoma	1
Recurrent Nasopharyngeal Carcinoma	1
Advanced Hepatocellular Carcinoma	1
Stage III Hepatocellular Carcinoma AJCC v8	1
Stage IV Hepatocellular Carcinoma AJCC v8	1
Metastatic Malignant Solid Neoplasm	1
Unresectable Malignant Solid Neoplasm	1
Pancreatic Adenocarcinoma	1
Stage II Pancreatic Cancer AJCC v8	1
Stage III Pancreatic Cancer AJCC v8	1
Stage IV Pancreatic Cancer AJCC v8	1
High Grade Glioma	1
Replication Repair Deficient	1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	1
Stage II Nasopharyngeal Carcinoma AJCC v8	1
Stage III Nasopharyngeal Carcinoma AJCC v8	1
Anal Melanoma	1
Bladder Melanoma	1
Cervical Melanoma	1
Esophageal Melanoma	1
Advanced Endometrial Carcinoma	1
Metastatic Endometrial Carcinoma	1
Recurrent Endometrial Carcinoma	1
Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8	1
Complete Surgical Resection	1
Circulating Tumor DNA	1
Anal Basaloid Carcinoma	1
Anal Canal Cloacogenic Carcinoma	1
Anal Margin Squamous Cell Carcinoma	1
Stage IIB Anal Cancer AJCC v8	1
Ann Arbor Stage III Hodgkin Lymphoma	1
Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma	1
Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma	1
Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma	1
Recurrent Squamous Cell Lung Carcinoma	1
Stage IV Squamous Cell Lung Carcinoma AJCC v7	1
Renal Cancer Metastatic	1
Lung Cancer, Nonsmall Cell	1
Non-Small Cell Lung Cancer NSCLC	1
Uterine Cervical Neoplasms	1
Urachal Cancer	1
Parathyroid Carcinoma	1
Fibrolamellar Carcinoma	1
Angiosarcoma	1
Clinical Stage III Esophageal Adenocarcinoma AJCC v8	1
Stage IIIA Lung Non-Small Cell Cancer AJCC v7	1
Cervical Adenocarcinoma	1
Cervical Adenosquamous Carcinoma	1
Recurrent Cervical Carcinoma	1
Stage IV Cervical Cancer AJCC v6 and v7	1
Resectable Lung Non-Small Cell Carcinoma	1
Stage II Lung Cancer AJCC v8	1
Stage IIIA Lung Cancer AJCC v8	1
Stage IIIB Lung Cancer AJCC v8	1
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma	1
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma	1
Stage IV Lung Cancer AJCC v8	1
Endometrial Adenocarcinoma	1
Endometrial Clear Cell Adenocarcinoma	1
Endometrial Dedifferentiated Carcinoma	1
Endometrial Endometrioid Adenocarcinoma	1
Refractory Hodgkin Lymphoma	1
Relapsed Hodgkin's Disease, Adult	1
Acinar Cell Carcinoma	1
Adenoid Cystic Carcinoma	1
Adrenal Cortical Carcinoma	1
Adrenal Gland Pheochromocytoma	1
Locally Advanced Bladder Urothelial Carcinoma	1
Locally Advanced Renal Pelvis Urothelial Carcinoma	1
Locally Advanced Ureter Urothelial Carcinoma	1
Locally Advanced Urethral Urothelial Carcinoma	1
Stage III Cutaneous Melanoma AJCC v7	1
Stage IV Cutaneous Melanoma AJCC v6 and v7	1
Recurrent Classic Hodgkin Lymphoma	1
Refractory Classic Hodgkin Lymphoma	1
Melanoma of Unknown Primary	1
Clinical Stage II Esophageal Adenocarcinoma AJCC v8	1
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	1
Recurrent Melanoma	1
Recurrent/ Metastatic Olfactory Neuroblastoma	1
Solid Neoplasms	1
Anaplastic Thyroid Cancer	1
Rhabdoid Tumor	1
Unresectable Colorectal Cancer	1
Richter's Transformation	1
Radiotherapy-Induced Immune Priming	1
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer	1
Endometrial Neoplasms	1
Endometrial Cancer	1
Locally Advanced Nasopharyngeal Carcinoma	1
Biliary Tract Cancer	1
Immune Checkpoint Inhibitor	1
Neoadjuvant Therapy	1
Hepatocellular Cancer	1
Colorectal Carcinoma	1
HIV I Infection	1
Glioblastoma Multiforme	1
Follicular Lymphoma Stage II	1
Follicular Lymphoma Stage III	1
Follicular Lymphoma Stage IV	1
Newly Diagnosed Glioblastoma	1
Malignant Glioma	1
Recurrent Glioblastoma	1
Recurrent Malignant Glioma	1
Melanoma Brain Metastases	1
HER2-Expressing Solid Tumors	1
Brain Metastases	1
Advanced Biliary Tract Cancer	1
Neuroendocrine Tumors	1
Female Reproductive System Neoplasm	1
MSI-H Solid Malignant Tumor	1
Advanced Glioblastoma	1
Metastatic Melanoma in the Central Nervous System	1
MGMT-Unmethylated Glioblastoma	1
Prostate Cancer	1
Hormone Sensitive Prostate Cancer	1
Prostate Adenocarcinoma	1
Metastasis Prostate Adenocarcinoma	1
Peritoneal Cancer	1
Metastatic Microsatellite Stable Colorectal Cancer	1
Ann Arbor Stage I Hodgkin Lymphoma	1
Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma	1
Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma	1
Ann Arbor Stage IA Hodgkin Lymphoma	1
Bladder Adenocarcinoma	1
Bladder Clear Cell Adenocarcinoma	1
Bladder Mixed Adenocarcinoma	1
Bladder Neuroendocrine Carcinoma	1
Renal Cancer	1
Papillary Renal Cell Carcinoma	1
Unclassified Renal Cell Carcinoma	1
Translocation Renal Cell Carcinoma	1
Chromophobe Renal Cell Carcinoma	1
Rectal Cancer	1
Genitourinary Cancer	1
Adrenocortical Carcinoma	1
Non-urothelial Bladder	1
Non-urothelial Upper Tract	1
TFE3-Rearranged Renal Cell Carcinoma	1
Metastatic Colon Adenocarcinoma	1
Metastatic Rectal Adenocarcinoma	1
Stage III Colon Cancer AJCC v8	1
Stage III Rectal Cancer AJCC v8	1
Skin Cancer	1
Pan-tumor	1
Advanced or Metastatic Solid Tumors	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	82	38
Clinical trials in Canada	66	32
Clinical trials in France	63	30
Clinical trials in Spain	62	28
Clinical trials in Australia	53	29
Clinical trials in Italy	50	24
Clinical trials in Israel	46	18
Clinical trials in Netherlands	43	24
Clinical trials in Germany	41	21
Clinical trials in Mexico	40	15
Clinical trials in UK	38	17
Clinical trials in Japan	36	19
Clinical trials in South Korea	35	17
Clinical trials in China	34	18
Clinical trials in Belgium	29	9
Clinical trials in Poland	29	15
Clinical trials in Brazil	28	14
Clinical trials in Taiwan	25	11
Clinical trials in Denmark	17	8
Clinical trials in Austria	17	9
Clinical trials in Czechia	17	6
Clinical trials in Norway	16	4
Clinical trials in Turkey	16	9
Clinical trials in Sweden	14	7
Clinical trials in Switzerland	12	6
Clinical trials in Egypt	12	2
Clinical trials in Singapore	11	4
Clinical trials in Portugal	9	6
Clinical trials in Ireland	7	3
Clinical trials in India	6	5
EU register (CTIS)	13	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Nivolumab trials

How many clinical trials are testing Nivolumab?

276 current trials in our USA, Canada, France, Spain, Australia, Italy, Israel, Netherlands, Germany, Mexico, UK, Japan, South Korea, China, Belgium, Poland, Brazil, Taiwan, Denmark, Austria, Czechia, Norway, Turkey, Sweden, Switzerland, Egypt, Singapore, Portugal, Ireland and India registers name Nivolumab (also registered as ABP 206) as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.

Are Nivolumab trials recruiting patients?

Yes. 125 of the 276 trials are recruiting: 38 with sites in USA, 32 with sites in Canada, 30 with sites in France, 28 with sites in Spain, 29 with sites in Australia, 24 with sites in Italy, 18 with sites in Israel, 24 with sites in Netherlands, 21 with sites in Germany, 15 with sites in Mexico, 17 with sites in UK, 19 with sites in Japan, 17 with sites in South Korea, 18 with sites in China, 9 with sites in Belgium, 15 with sites in Poland, 14 with sites in Brazil, 11 with sites in Taiwan, 8 with sites in Denmark, 9 with sites in Austria, 6 with sites in Czechia, 4 with sites in Norway, 9 with sites in Turkey, 7 with sites in Sweden, 6 with sites in Switzerland, 2 with sites in Egypt, 4 with sites in Singapore, 6 with sites in Portugal, 3 with sites in Ireland and 5 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Nivolumab clinical trials?

National Cancer Institute (NCI) (35), Bristol-Myers Squibb (24), Ono Pharmaceutical Co., Ltd (11) and The Netherlands Cancer Institute (9), among 143 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Nivolumab clinical trials in Ireland?

Yes. 7 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Nivolumab licensed in Ireland?

Yes. The HPRA medicines list includes 3 single-substance products containing Nivolumab, for example OPDIVO 10 mg/mL concentrate for solution for infusion (Bristol-Myers Squibb Pharma EEIG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Nivolumab shortage?

Not in the lists we track: Nivolumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nivolumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nivolumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nivolumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Nivolumab clinical trials

Where Nivolumab is approved

What health systems spend on Nivolumab

How Nivolumab works

NICE appraisals of Nivolumab

Patient leaflets for Nivolumab

Reference identifiers for Nivolumab

Trials by status

Trials by phase

Clinical trials of Nivolumab

Nivolumab in the EU trials register (CTIS)

Nivolumab across our data

Licensed in Ireland (HPRA)

Supply shortages

Conditions studied with Nivolumab

Sponsors

By country register

Related compounds

In the same trials as Nivolumab

Other compounds in Melanoma trials

Questions about Nivolumab trials

How this page is built